These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37041868)

  • 1. Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin.
    Yamanaka T; Takeshita K; Mochizuki T; Inoue H; Akiyama T
    Spine Surg Relat Res; 2023 Mar; 7(2):136-141. PubMed ID: 37041868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study.
    Akazawa T; Inoue G; Tanaka M; Umehara T; Nagai T; Oshita Y; Imura T; Miyagi M; Saito W; Sako K; Nomura S; Hiyama A; Katoh H; Sakai D; Sato M; Yoshida A; Iinuma M; Niki H; Takaso M; Watanabe M
    Global Spine J; 2023 Jun; 13(5):1319-1324. PubMed ID: 34325544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.
    Tetsunaga T; Tetsunaga T; Nishida K; Misawa H; Takigawa T; Yamane K; Tsuji H; Takei Y; Ozaki T
    J Orthop Surg Res; 2020 May; 15(1):191. PubMed ID: 32456647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study).
    Kimura Y; Yamaguchi S; Suzuki T; Kato J; Chiba S; Hirakawa N; Yamaguchi K; Tanabe Y; Takatsuna H; Kenyoshi Y; Shiosakai K; Sakai M; Iseki M
    Pain Ther; 2021 Jun; 10(1):711-727. PubMed ID: 33856660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta-analysis of randomised controlled trials.
    Alyoubi RA; Alshareef AA; Aldughaither SM; Aljaroudi AM; Alabdulwahed A; Alduraibi FM; Masoud AT; Abu-Zaid A
    Int J Clin Pract; 2021 May; 75(5):e13744. PubMed ID: 32991782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
    Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
    Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy.
    Hong LM; Liu JM; Lin L; Huang CC; Chen R; Lin WW
    Eur J Pharm Sci; 2024 Jun; 197():106777. PubMed ID: 38649099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of mirogabalin and pregabalin in Japanese patients with neuropathic pain: a retrospective cohort study.
    Nakajima R; Ooba N; Kamei M; Hashiba H; Miyazaki C
    Expert Opin Drug Saf; 2023; 22(9):841-848. PubMed ID: 36945742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study.
    Nikaido T; Takatsuna H; Tabata S; Shiosakai K; Nakatani T; Konno SI
    Pain Ther; 2022 Dec; 11(4):1195-1214. PubMed ID: 35857196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
    Vinik A; Rosenstock J; Sharma U; Feins K; Hsu C; Merante D;
    Diabetes Care; 2014 Dec; 37(12):3253-61. PubMed ID: 25231896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
    Hutmacher MM; Frame B; Miller R; Truitt K; Merante D
    J Clin Pharmacol; 2016 Jan; 56(1):67-77. PubMed ID: 26073181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study.
    Baba M; Kuroha M; Ohwada S; Murayama E; Matsui N
    Pain Ther; 2020 Jun; 9(1):261-278. PubMed ID: 32052264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
    Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
    BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study.
    Merante D; Rosenstock J; Sharma U; Feins K; Hsu C; Vinik A;
    Pain Med; 2017 Nov; 18(11):2198-2207. PubMed ID: 28371941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of a new voltage-gated Ca
    Kato J; Inoue T; Yokoyama M; Kuroha M
    Expert Opin Pharmacother; 2021 Dec; 22(17):2311-2322. PubMed ID: 34431423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west.
    Ogawa S; Satoh J; Arakawa A; Yoshiyama T; Suzuki M
    Drug Saf; 2012 Oct; 35(10):793-806. PubMed ID: 22967187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit.
    Zajączkowska R; Mika J; Leppert W; Kocot-Kępska M; Malec-Milewska M; Wordliczek J
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33572689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
    Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
    Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery: the multicenter, randomized, open-label ADMIT-NeP study.
    Miyazaki T; Matsumoto K; Sato T; Sano I; Furukawa K; Shimoyama K; Kamohara R; Suzuki M; Kondou M; Ikeda N; Tabata S; Shiosakai K; Nagayasu T;
    BMC Cancer; 2024 Jan; 24(1):80. PubMed ID: 38225552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain.
    Zajączkowska R; Pawlik K; Ciapała K; Piotrowska A; Ciechanowska A; Rojewska E; Kocot-Kępska M; Makuch W; Wordliczek J; Mika J
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.